ZOOZ Strategy Announces Review and Evaluation of Strategic Alternatives to Complement Bitcoin Strategy

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) — ZOOZ Strategy Ltd. (Nasdaq and TASE: ZOOZ) (“ZOOZ” or the “Company”) today announced that its Board of Directors has authorized management to explore a range of strategic alternatives that could potentially complement the Company’s existing bitcoin treasury strategy and enhance long-term shareholder value.

Phemex Enhances Prediction Markets with Strategic Navigation and Curated Event Discovery

APIA, Samoa, June 10, 2026 (GLOBE NEWSWIRE) — Phemex, a user-first crypto exchange,has announced a significant upgrade to its Prediction Markets platform, introducing advanced features designed to streamline the intersection of information and execution. As global markets and sporting events become increasingly complex, Phemex is refining how its 10 million users interact with real-world outcomes, ensuring that every participant can navigate high-stakes events with greater precision and structural clarity.

Phemex Enhances Prediction Markets with Strategic Navigation and Curated Event Discovery

APIA, Samoa, June 10, 2026 (GLOBE NEWSWIRE) — Phemex, a user-first crypto exchange,has announced a significant upgrade to its Prediction Markets platform, introducing advanced features designed to streamline the intersection of information and execution. As global markets and sporting events become increasingly complex, Phemex is refining how its 10 million users interact with real-world outcomes, ensuring that every participant can navigate high-stakes events with greater precision and structural clarity.

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway inhibitors continue to dominate across mHSPC and mCRPC settings, the emergence of novel therapies such as 225Ac PSMA 617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma, and Takeda), and others is significantly reshaping the treatment paradigm.

The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway inhibitors continue to dominate across mHSPC and mCRPC settings, the emergence of novel therapies such as 225Ac PSMA 617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma, and Takeda), and others is significantly reshaping the treatment paradigm.

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

The lupus nephritis clinical trial analysis report delivers important insights into ongoing research of 35+ pipeline lupus nephritis drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

The lupus nephritis clinical trial analysis report delivers important insights into ongoing research of 35+ pipeline lupus nephritis drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

FASTECH and Bosch Rexroth to Build World’s Largest Hydrogen Refueling Station for Transit Buses

San Mateo County, California, USA, June 10, 2026 (GLOBE NEWSWIRE) — FASTECH, in collaboration with Bosch Rexroth, announced that they have been contracted by the San Mateo County Transit District (SamTrans) to design, build, and commission a large-scale hydrogen refueling station, featuring Bosch Rexroth’s innovative CryoPump system technology to support transit bus operations.

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026.